Psychiatric Times

06/05/2026

🎙️🧐💊 This week's "Brain Trust" episode is now live!

Joseph Goldberg and guest Robert M. Post, MD, discuss evolving perspectives on bipolar disorder and treatment, emphasizing early intervention and the underutilization of lithium:

Experts urge early bipolar disorder treatment, highlighting lithium’s underuse despite neuroprotective, antisuicidal benefits and evidence that delays worsen outcomes and responsiveness.

06/04/2026

Phase 2 topline data show that elunetirom for the treatment of bipolar depression achieved statistical significance across the primary and all key secondary depression endpoints.

Phase 2 trial shows elunetirom rapidly eases bipolar depression symptoms with strong response, good tolerability, and FDA Fast Track momentum.

06/02/2026

The FDA has issued a Complete Response Letter for CTx-1301, a novel formulation of dexmethylphenidate for treatment of ADHD.

FDA issues CRL for CTx-1301 in ADHD.

06/01/2026

Our June theme: Special Populations.

We want to hear your clinical insights! Submit to our content series ⬇️ https://www.psychiatrictimes.com/view/presenting-our-june-2026-theme-special-populations

05/25/2026

This Memorial Day, Psychiatric Times honors the brave individuals who made the ultimate sacrifice in service to our country. We remember their courage, reflect on their legacy, and express gratitude to all who have served.

05/22/2026

🎙️🧐💊 This week's "Brain Trust" episode is now live!

Guest Michael Gitlin, MD, shares insights on the complex psychopharmacology of personality disorders:

Explore psychopharmacologic options for personality disorders in this podcast.

05/22/2026

Antipsychotic medications are the cornerstone of treatment and remain the most effective intervention for reducing psychotic symptoms and preventing relapse. Yet medication alone is often insufficient. Psychotherapy, when integrated thoughtfully with biological treatment, can play an important role in relapse prevention and long-term recovery.

Read more from Mark L. Ruffalo and Trisha Ruffalo, LCSW here: https://www.psychiatrictimes.com/view/psychotherapy-and-the-prevention-of-relapse-in-schizophrenia

05/21/2026

The HHS has released the Surgeon General’s “Warning on the Harms of Screen Use," which aims to raise national awareness about the growing risks associated with excessive and harmful screen use among youth.

New Surgeon General advisory warns of youth screen and social media harms, urging families, schools, and clinicians to act with the 5 Ds.

05/21/2026

Need new reading material? The entire May 2026 issue of Psychiatric Times is now live on our website. Read it here: https://www.psychiatrictimes.com/journals/psychiatric-times/vol-43-issue-5

05/20/2026

The latest focus on psychedelic use for mood disorders and continued research into neuromodulation holds much potential, says Gus Alva, MD. https://www.psychiatrictimes.com/shorts/future-of-psychedelics-and-brain-stimulation